Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Adjuvant HER2+ Breast Cancer
NCT00625898Phase 3Terminated
- Sponsor
- NSABP Foundation
- Start
- Apr 2008
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 40
01
Overview
A Phase 3 trial of bevacizumab in breast cancer, sponsored by NSABP Foundation. Started Apr 2008; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00625898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625898.